iBio’s IBIO-610 Achieves 98% Activin E Inhibition for Eight Weeks in NHPs
IBIO•Single-dose IBIO-610 achieved up to 98% active Activin E inhibition at weeks 4 and 8 in obese non-human primates, maintaining suppression through eight weeks. Combined with semaglutide, IBIO-610 enhanced visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone.
1. Robust Activin E Inhibition
Following a single dose of IBIO-610 in obese non-human primates, active Activin E was suppressed by 98% at week 4 and 97% at week 8 versus baseline, maintaining levels below assay detection through eight weeks.
2. Combination Therapy Outcomes
When combined with semaglutide, IBIO-610 produced greater visceral and total fat loss while reducing lean mass loss by 73% compared to semaglutide alone, indicating a fat-selective weight loss profile.
3. Potential Clinical Implications
These data support IBIO-610’s potential as a long-acting antibody therapy with low-frequency dosing and differentiated pathway inhibition in obesity and cardiometabolic disorders, paving the way for human studies.
4. Upcoming Data Presentation
Full preclinical results will be presented at the European Association for the Study of Diabetes annual meeting in Milan on October 1 during a short oral discussion session.
